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OBJECTIVE: NICE was established in the UK in 1999 to
make recommendations about technology adoption based
on effectiveness and cost-effectiveness evidence. The ABPI
has expressed concern that these requirements will ex-
tend product development times and increase develop-
ment costs. This will depend upon the role NICE expects
randomized controlled trials (RCTs) to play in the pro-
duction of cost-effectiveness evidence, particularly at the
time of launch. However, NICE have not yet issued de-
tailed guidance on economic evaluation methodology.
Therefore this paper assesses whether a requirement for
trial-based economic evidence would increase sample sizes
since these are a major determinant of development times
and costs. METHODS: The University of York Centre
for Reviews and Dissemination (CRD) database was used
to identify studies, which had collected economic data
alongside RCTs, presented cost-effectiveness ratios and
reported variances. Publications pertaining to them were
retrieved and the data relevant for sample size calcula-
tions were extracted. Recently published sample size for-
mulae based on the net health benefits approach were
used to calculate the number of subjects which would
have been required for testing cost-effectiveness hypothe-
ses. These were compared with those used to evaluate the
clinical outcomes in the original trials. RESULTS: For
each of the studies surveyed, sample sizes would have
been significantly greater for performing cost-effective-
ness studies than for performing the original clinical trials
of which they were a part. However, they are sensitive to
the choice of the ratio of acceptable cost-effectiveness
used in the calculations. CONCLUSIONS: If NICE issues
guidance which requires cost-effectiveness evidence based
on RCTs to be of the same standard used in the classical
approach to clinical evaluations, then the required sam-
ple sizes, and hence costs, will most likely be higher than
those required for purely clinical evaluation. Larger sam-
ple sizes are also likely to extend the period of recruit-
ment and hence development times.
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OBJECTIVE: To investigate the extent to which claims
of efficacy in applications for requesting the addition of
new drugs to the formulary of the Australian Pharmaceu-
tical Benefits Scheme have been based on surrogate out-
come data. METHODS: Analyses were drawn from a da-
tabase of all submissions for new drug/indication pairs
considered between 1993 and 1998. Applications were
classified according to whether the data presented were
based on clincal, intermediate or surrogate endpoints.








for those drugs subsequently listed. RESULTS: Of more
than 400 submissions considered, 216 were initial sub-
missions for drug/indication pairs and 150/216 [69%]
were subsequently recommended for addition to the for-
mulary. Of those recommended for listing, 36/150 [24%]
applications presented claims of efficacy data that were
wholly dependent on surrogate endpoint data, and 68/
150 [45%] submissions relied on a combination of surro-
gate with intermediate and/or clinical endpoint data. Sev-
enty-four (49%) submissions presented some clinical end-
point data, but only 30/150 (20%) submissions were
based on clinical endpoint data alone. In calendar 1999
more than AUD 420 million was spent on drugs whose
efficacy had only been demonstrated against surrogate
endpoints, approximately one sixth of annual expendi-
ture. DISCUSSION: Decision-makers must at times con-
sider the adoption of therapies for which only surrogate
outcome data are available. Uncertainties inherent in esti-
mates of comparative efficacy and cost-effectiveness are
magnified when data are drawn from clinical trials that
report only surrogate outcome data. Comparative cost-
effectiveness analysis cannot give rise to technical or al-
locative efficiencies if the criteria on which assessments
are based are unreliable.
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Member satisfaction with health care delivered in man-
aged care organizations (MCOs) can have profound ef-
fects on the health outcomes for patients. In the U.S.,
health employer data information sets (HEDIS) guide-
lines list satisfaction with pharmacy services as an indica-
tor of quality of care. Pharmacy services are an important
component of health care benefits, and are frequently
listed as a patient dissatisfier. Dissatisfaction with phar-
maceutical care can lead to noncompliance, nonpersis-
tence, and delay necessary therapies. Increasingly, report
card type measurements are included as a segment of
MCO National Committee for Quality Assurance (NCQA)
accreditation evaluations. OBJECTIVES: The study pur-
pose was to assess satisfaction with pharmacy services in
two populations of a large MCO as a NCQA quality im-
provement/preventive health activity project. METHODS:
Patients using pharmaceutical services in varying practice
sites were surveyed via a mailed questionnaire to deter-
mine satisfaction with MCO pharmacy services. Statistical
analyses included use of analysis of variance (ANOVA)
with Tukey HSD follow-up tests, and chi-square compar-
isons. RESULTS: A 68% percent response rate was reached
with both surveys. In two U.S. metropolitan areas, satis-
faction with pharmacy services exceeded 80% in a sam-
ple of 2,500 patients with no gender or age differences in
levels of satisfaction. However, satisfaction with specific
types of pharmacies (independent community, food mar-
ket, chain community) was significantly different (P 
0.01) as analyzed via ANOVA for specific and general
components of pharmaceutical care delivery. Tukey HSD
follow up tests indicated a significantly lower level of sat-
isfaction in chain community pharmacies when com-
pared with the two other pharmacy types. A Pearson’s
correlation noted a directly positive relationship between
self-assessed health status and satisfaction with pharmacy
services (r  0.154, P  0.001). CONCLUSIONS: Satis-
faction with pharmacy services can be high in general in
MCOs, but it is important to further study levels of satis-
faction based on pharmacy type and patient health status.
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OBJECTIVES: To examine trends and ethnic differences
in ‘amenable’ mortality and to estimate the relative im-
pact of health care interventions in terms of gains in mor-
tality outcomes. METHODS: The method is based on the
premise that death from certain conditions should not
happen given appropriate and timely health care inter-
ventions. Age-standardized mortality rates per 100,000-
population were calculated for 16 ‘amenable’ causes of
death for six 5-year periods from 1965 to 1994, and for
each of the three major ethnic groups (Chinese, Malays
and Indians) for three 3-year periods from 1989 to 1997.
The rates were divided into those, which can be reduced
by timely therapeutic care for ‘treatable’ conditions (such
as asthma and appendicitis), or by primary preventive
measures for ‘preventable’ conditions (such as lung can-
cer and motor vehicle injury). RESULTS: Amenable mor-
tality was 43.2% of all-causes deaths. The rate was
higher in males (109.7) than in females (60.7). Amenable
mortality showed annual declines of 1.98% in males and
1.94% in females, while those in ‘non-amenable’ mortal-
ity were 1.08% and 1.37% respectively. The decline in
amenable mortality was contributed much more by the
decline in mortality from ‘treatable’ causes, than that from
‘preventable causes.’ By evaluating the decline in amenable
mortality relative to that in non-amenable mortality, it
would appear that there was a greater impact of health
care in males (27.0%) than in females (16.6%) between
1965 and 1994. Amenable mortality was lowest for Chinese,
and highest for Malays. Over the recent 9-year period
(1989–97), amenable mortality declined more in Chinese,
than in Malays and Indians. However, when concomi-
tant decline in non-amenable mortality was taken into
account, Malays have made the most gains from health
care interventions. CONCLUSION: In line with the find-
ings from European countries, amenable mortality in Sin-
gapore declined more than non-amenable mortality.
There were more significant gains in mortality outcomes
